Protara Therapeutics (TARA) EPS (Weighted Average and Diluted) (2021 - 2026)
Protara Therapeutics (TARA) recorded quarterly EPS (Weighted Average and Diluted) of -$0.31 in Q1 2026, up 18.42% quarter-over-quarter from -$0.38 in Q4 2025, and down 6.9% on a YoY basis from -$0.33 in Q1 2025.
Protara Therapeutics (TARA) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Protara Therapeutics' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.31 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 6.9% year-over-year to -$0.31; the TTM figure through Mar 2026 stood at -$1.35 (up 19.16% YoY), while the FY2025 annual figure was -$1.34, up 38.25% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.31 for Q1 2026 at Protara Therapeutics, up from -$0.38 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.29 in Q1 2025 to a low of -$3.46 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.79 across 5 years, with a median of -$0.68 in 2022.
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) plunged 280.22% in 2022, then jumped 73.99% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$3.46 in 2022, then surged by 73.99% to -$0.9 in 2023, then surged by 52.22% to -$0.43 in 2024, then increased by 11.63% to -$0.38 in 2025, then gained by 18.42% to -$0.31 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.31 (Q1 2026), -$0.38 (Q4 2025), and -$0.31 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Protara Therapeutics | 229.00 Mn | 229.00 Mn | - | -0.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.31 |
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | -0.35 |
| Mar 31, 2025 | -0.29 |
| Dec 31, 2024 | -0.43 |
| Sep 30, 2024 | -0.50 |
| Jun 30, 2024 | -0.45 |
| Mar 31, 2024 | -0.97 |
| Dec 31, 2023 | -0.90 |
| Sep 30, 2023 | -0.87 |
| Jun 30, 2023 | -1.00 |
| Mar 31, 2023 | -0.80 |
| Dec 31, 2022 | -3.46 |
| Sep 30, 2022 | -0.68 |
| Jun 30, 2022 | -0.76 |
| Mar 31, 2022 | -0.96 |
| Dec 31, 2021 | -0.91 |
| Sep 30, 2021 | -0.96 |
| Jun 30, 2021 | -1.14 |